LogicBio Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q3 2017 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
LogicBio Therapeutics, Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q3 2017 to Q3 2022.
  • LogicBio Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2022 was -$5.78M, a 43.3% increase year-over-year.
  • LogicBio Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2022 was -$26.5M, a 29.9% increase year-over-year.
  • LogicBio Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$40M, a 22.7% decline from 2020.
  • LogicBio Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$32.6M, a 18.7% increase from 2019.
  • LogicBio Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2019 was -$40.1M, a 128% decline from 2018.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$26.5M -$5.78M +$4.41M +43.3% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$31M -$5.04M +$5.46M +52% Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q1 2022 -$36.4M -$6.66M +$3.62M +35.2% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 -$40M -$9.06M -$2.16M -31.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-04
Q3 2021 -$37.9M -$10.2M -$2.15M -26.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$35.7M -$10.5M -$2.27M -27.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$33.4M -$10.3M -$827K -8.75% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$32.6M -$6.9M +$4.57M +39.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-04
Q3 2020 -$37.2M -$8.04M +$2.89M +26.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$40.1M -$8.23M +$1.79M +17.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$41.9M -$9.46M -$1.77M -23% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$40.1M -$11.5M -$4.4M -62.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-15
Q3 2019 -$35.7M -$10.9M -$6.27M -134% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$29.4M -$10M -$6.43M -179% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$23M -$7.69M -$5.39M -235% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$17.6M -$7.07M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$4.66M -$3.65M -361% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$3.59M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$2.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 -$1.01M Jul 1, 2017 Sep 30, 2017 10-Q 2018-12-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.